Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
Molecular and Cellular Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Methods Mol Biol. 2023;2693:209-219. doi: 10.1007/978-1-0716-3342-7_16.
We have developed an enhanced molecular chaperone-based vaccine through rapid isolation of Hsp70 peptide complexes after the fusion of tumor and dendritic cells (Hsp70.PC-F). In this approach, the tumor antigens are introduced into the antigen-processing machinery of dendritic cells through the cell fusion process, and thus we can obtain antigenic tumor peptides or their intermediates that have been processed by dendritic cells. Our results show that Hsp70.PC-F has increased immunogenicity compared to preparations from tumor cells alone and therefore constitutes an improved formulation of the chaperone protein-based tumor vaccine.
我们通过融合肿瘤细胞和树突状细胞(Hsp70.PC-F)后快速分离 Hsp70 肽复合物,开发了一种增强型分子伴侣基疫苗。在这种方法中,通过细胞融合过程将肿瘤抗原引入树突状细胞的抗原加工机制,从而可以获得已被树突状细胞加工的抗原性肿瘤肽或其中间产物。我们的结果表明,与单独来自肿瘤细胞的制剂相比,Hsp70.PC-F 具有更高的免疫原性,因此构成了基于伴侣蛋白的肿瘤疫苗的改进制剂。